Printer Friendly

Research and Markets: Women's Infertility - Drug Pipeline Analysis and Market Forecasts Through to 2016.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/ff6fe1/Women's_infertilit) has announced the addition of GlobalData's new report "Women's Infertility - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering.

Women's Infertility - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global Women's infertility market. The report identifies the key trends shaping and driving the dynamism in the global Women's infertility market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Women's infertility market.

The Women's Infertility Market is Estimated to Decline until 2016

GlobalData estimates that the global Women's infertility market was valued at $1.08 billion in 2009 and is forecast to decline at a compound annual growth rate (CAGR) of -10% to reach $520m by 2016. The decline in market growth is primarily due to strong market competition and the entry of generics. Some key branded products such as Cetrotide, GONAL-f, Crinone, Ovidrel, Luveris, Pergoveris and Puregon are going to face severe threats from generics as they approach patent expiry between 2010 and 2015. Although the incidence and prevalence of the condition are increasing, the reducing drug prices are allowing the market to decline.

Global Women's Infertility Market Forecast, Revenues ($m), 2001-2016

Current Treatment Options Cater to Most of the Market Needs

GlobalData finds that the women's infertility market is highly competitive with highly successful branded drugs and generics. The market is dominated by some key therapies such as clomiphene citrate, human chorionic gonadotropin (hCG), gonadotrophin-releasing hormone antagonists (GnRH), human menopausal gonadotropin (hMG), and follicle stimulating hormones. All of the therapies that are available to treat infertility in women are highly efficacious and safe. The current drugs serve almost all of the available opportunities in the market and therefore leave low unmet needs.

Meningitis Market - Opportunity and Unmet Need, 2010 Women's Infertility Drug Development Landscape is Highly Competitive

The market is highly competitive, with Merck Serono and Ferring Pharmaceuticals dominating the market with the highest number of marketed products. GlobalData predicts that Merck Serono SA, Ferring Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd. and PregLem SA will become the leading competitors in the global women's infertility market. The current competitive landscape is populated with more than 10 branded dugs and few generics, which are significantly strong.

Weak Pipeline Candidates Raise Little Hope for the Women's Infertility Market

Analysis shows that products for women's infertility in the developmental pipeline are weak with 16 molecules in various phases of clinical development, including three first-in-class molecules. The women's infertility pipeline lacks innovation and the development of first-in-class molecules with better safety and efficacy profiles. The pipeline includes GnRH antagonists, AMP-activated protein kinase (AMPK) agonists, luteinizing hormone (LH) stimulators and beta-2 receptor agonists for the treatment of infertility in women.

Scope:

* Annualized global women's infertility disease market revenues data from 2001 to 2009, forecast for seven years to 2016.

* Geographic markets covered in this report are the US, the UK, Italy, Spain, Germany, France, and Japan.

* Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include GnRH antagonists, AMP-activated protein kinase (AMPK) agonists, luteinising hormone stimulators and Beta 2 receptor agonists.

* Analysis of the current and future competitors in the global women's infertility market. The key market players covered are Merck Serono SA, Ferring Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd. and PregLem SA.

* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

* The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future women's infertility market.

Key Topics Covered:

1 Table of contents

2 Women's Infertility: Market Characterization

3 Women's Infertility Market: Competitive Assessment

4 Women's Infertility Market: Pipeline Assessment

5 Global Women's Infertility Market: Implications for Future Market Competition 6 Global Women's Infertility Market: Future Players in the Women's Infertility Market

7 Global Women's Infertility Market: Appendix

Companies Mentioned:

* Merck Serono S.A.

* Dong-A Pharmaceutical Co., Ltd.

* Ferring Pharmaceuticals

* PregLem SA

For more information visit http://www.researchandmarkets.com/research/ff6fe1/Women's_infertilit
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 14, 2010
Words:721
Previous Article:UTOPY Named 2010 CRM Excellence Winner by Customer Interaction Solutions Magazine.
Next Article:Research and Markets: Trends in Selective Soldering - Lead-free Initiatives Creates Increased Opportunities for Selective Soldering Technology.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters